Insights - Agios Pharmaceuticals (AGIO) soared in trading on Monday after reporting Phase 1 data demonstrating that its cancer metabolism drug AG-221, a first-in-class inhibitor of IDH2 … Continue Reading
Read nowRecap - Continued weakness in the healthcare sector this week was marked on Friday by the iShares Biotech Index’s (IBB) break of a key uptrend and support level, suggesting … Continue Reading
Read nowResearch - – Despite post-earnings selloff, longterm outlook remains intact. MDVN is an attractive part of a core healthcare portfolio. – Off-putting 2014 Xtandi guidance may prove … Continue Reading
PremiumInsights - Acorda is one of just a few CNS players remaining since large pharma culled the difficult segment from their R&D budgets in the last few years. Here's what makes it interesting.
Read nowResearch - Back by government defense contracts, this developer of biodefense drugs and vaccines has real staying power.
Read nowInsights - Alexion (ALXN) raised guidance this week with reimbursement news from France. Here's more on the company's 2014.
Read nowRecap - Just remember – it’s not a win until you’ve locked in those profits. Buying Retrophin (RTRX) when PropThink suggested going long the stock on the day it up-listed to … Continue Reading
Read now
